Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Buprenorphine for the treatment of pain in patients with central nervous system tumors: A case series.

Neuro-oncology practice·2026

Same author

Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States.

Gynecologic oncology·2026

Same author

Development of a benchmarking dataset for symptom detection using large language models.

JAMIA open·2026

Same author

Characteristics, Diagnosis, and Treatment of Aphasia in Patients With Brain Tumors: A Scoping Review.

Neurology·2026

Same author

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026

Same author

Palliative Care for Older Adults With Hip Fracture: An Explanatory Sequential Mixed-Methods Study.

Journal of pain and symptom management·2026

Search research articles

Related Experiment Videos

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC): A Randomized Clinical Trial.

Christopher R Manz^1,2,3, Cody E Cotner^2,3, Angela C Tramontano¹

¹1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Journal of the National Comprehensive Cancer Network : JNCCN

|June 15, 2026

Summary

Combined clinician and patient nudges significantly increased serious illness conversations (SICs) rates within 60 days. Natural language processing (NLP) enhanced SIC detection, highlighting its value in clinical notes.

Related Experiment Videos

Area of Science:

Oncology
Health Services Research
Palliative Care

Background:

Serious illness conversations (SICs) are crucial for aligning care with patient preferences but occur infrequently.
There is a need for sustainable interventions to increase the uptake of SICs in oncology settings.

Purpose of the Study:

To evaluate the effectiveness of combined clinician and patient nudges in increasing the rates of documented serious illness conversations.
To assess the utility of natural language processing (NLP) in identifying SICs within electronic health records.

Main Methods:

A pragmatic 4-arm randomized controlled trial involving 1,051 adult oncology patients at high risk.
Interventions included mailed patient nudges, clinician email reminders, combined nudges, or no nudges.
Outcomes measured were the proportion of patients with documented Advance Care Planning-Serious Illness Conversations (ACP-SICs) and ACP-SICs identified via NLP within 60 days.

Main Results:

The combined-nudge group showed significantly higher ACP-SIC rates (17.3%) compared to the control group (10.7%; P=.045).
ACP + NLP-SIC rates were also significantly higher in the combined-nudge group (32.5%) versus control (22.6%; P=.01).
Individual clinician or patient nudges did not significantly increase SIC rates compared to the control.

Conclusions:

Combined clinician and patient nudges effectively increase serious illness conversation documentation.
The clinician nudge component was the primary driver of the observed increase in SIC rates.
NLP significantly enhances the detection of SICs, underscoring the importance of analyzing free-text clinical notes.